Neurobehavioral manifestations of symptomatic HIV-1 disease in children: can nutritional factors play a role?
Central nervous system (CNS) abnormalities are significant and frequent complications of human immunodeficiency virus (HIV-1) infection in infants and children. Although the predominant cause of neurological and neuropsychological abnormalities appears to be related to HIV infection of the CNS, other factors including malnutrition may also play a role. We retrospectively evaluated the association of change in body weight with changes in neurocognitive function, ventricular brain ratio, and cerebrospinal quinolinic acid levels in a small cohort of children (n=15; mean age 6.3 years) with symptomatic HIV-1 disease before and after 6 months of antiretroviral therapy with continuous intravenous infusion of zidovudine (ZVD). Significant increases in weight and neurocognitive function as well as decreases in ventricular brain ratio and cerebrospinal quinolinic acid levels were noted after therapy. Only the relation between increase in weight and decrease in ventricular brain ratio was statistically significant (P< .01); contrary to expectations, an increase in weight seemed to correlate with a decrease in neurocognitive function (NS). Another group of children treated at the same time with oral intermittent ZVD, but otherwise receiving the same care did not show the same magnitude of improvement in neurocognitive function. These results seem to suggest that general supportive and medical care as well as nutritional factors may only play a limited role in the neurocognitive improvements after antiretroviral therapy with continuous infusion ZVD. Our sample size was, however, small and the nutritional measure rather global; thus these findings have to be considered as very preliminary.
Brouwers
P
P
Pediatric Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Decarli
C
C
Heyes
M P
MP
Moss
H A
HA
Wolters
P L
PL
Tudor-Williams
G
G
Civitello
L A
LA
Pizzo
P A
PA
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy; D002648:Child; D002652:Child Behavior; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology*; D015497:HIV-1; D006801:Humans; D009483:Neuropsychological Tests; D009748:Nutrition Disorders / Q000150:complications; D015215:Zidovudine / Q000627:therapeutic use
D015215:Zidovudine